Biomedical R&D - Coronavirus Contracts

Contracts Vendors Agencies Categories States

Coronavirus Contracts

Tracking Federal Purchases to Fight the Coronavirus

Home › All Categories › Category ›

Biomedical R&D

Total Committed Value of Federal Contracts

$206M

Total Contracts

Total Actions

119

Recent Contract Actions

Contracts can have multiple “contract actions”: This is how agencies spend money for a specific purpose, adjust the amount committed or change the contract in a way that doesn’t affect the amount. That last scenario is usually indicated by a $0 action. If there is a contract action for a negative amount, it generally means the contract was adjusted or canceled.

Description	Vendor	Agency	Effective	Estimated completion	Amount Committed
PRE-CLINICAL MODELS OF INFECTIOUS DISEASES - ESTABLISHMENT OF SMALL ANIMAL MODELS FOR SCREENING MCMS FOR THE 2019 NOVEL CORONAVIRUS (SARS-COV-2)	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	National Institutes of Health	March 23, 2020	November 30, 2021	$0
NEW AWARD E-09	EUROFINS PANLABS, INC.	National Institutes of Health	July 14, 2021	July 14, 2022	$133,500
COVID WASTEWATER	UNIVERSITY OF LOUISVILLE	Centers for Disease Control and Prevention	March 25, 2021	November 21, 2021	$0
PROSPECTIVE, NATURAL HISTORY STUDY OF SARS COV-2 INFECTION IN WAKE FOREST HEALTH CARE WORKERS USING INNOVATIVE SAMPLING KITS	VYSNOVA PARTNERS, INC.	Centers for Disease Control and Prevention	July 01, 2020	June 30, 2022	-$46
MIS-C IN CHILDREN	CHILDREN'S HOSPITAL CORPORATION, THE	Centers for Disease Control and Prevention	May 05, 2021	May 04, 2022	$8,996,605
BIOSTATISTICIAN SERVICES	EMDX RESEARCH AND CONSULTING ASSOCIATES, LLC	Department of Veterans Affairs	May 01, 2021	October 31, 2021	$100,157
PCMID - ESTABLISHMENT OF SMALL ANIMAL MODELS FOR SCREENING MCMS FOR THE 2019 NOVEL CORONAVIRUS (SARS-COV-2)	COLORADO STATE UNIVERSITY	National Institutes of Health	March 23, 2020	June 30, 2021	$0
PERFORM HIGH THROUGHPUT IN VIVO EFFICACY TESTING OF THERAPEUTIC CANDIDATES AGAINST SARS-COV-2	UTAH STATE UNIVERSITY	National Institutes of Health	March 29, 2021	March 28, 2022	$379,235
A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION	CHRYSALIS BIOTHERAPEUTICS, INC.	National Institutes of Health	January 30, 2017	August 31, 2021	$0
COVID WASTEWATER	UNIVERSITY OF LOUISVILLE	Centers for Disease Control and Prevention	March 25, 2021	November 21, 2021	$8,665,208
TO ISSUE A NO COST EXTENSION TO THE BASE OF THE TASK ORDER FROM MARCH 22, 2021 TO JUNE 22, 2021;	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	National Institutes of Health	March 23, 2020	March 22, 2021	$0
CHARACTERIZE SEROPREVALENCE OF SARS COV-2 ANTIBODIES IN THE US POPULATION	VITALANT	Centers for Disease Control and Prevention	May 12, 2020	May 11, 2022	$11,221,162
VIRUS GENOMICS AND HUMAN MOBILITY REVEAL THE PATTERNS SARS-COV-2 SPREAD	YALE UNIVERSITY	Centers for Disease Control and Prevention	September 22, 2020	September 20, 2022	$0
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION	SOUTHERN RESEARCH INSTITUTE	National Institutes of Health	March 27, 2020	May 26, 2021	$148,678
TO INCREASE FUNDS TO THE CONTRACT.	ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE	National Institutes of Health	March 27, 2020	May 31, 2021	$898,325
THE PURPOSE OF THIS MODIFICATION IS TO INCORPORATE A NO ADDITIONAL COST EXTENSION TO OPTIONS 1 AND 3C.	BATTELLE MEMORIAL INSTITUTE	National Institutes of Health	March 27, 2020	May 27, 2021	$0
CHEMISTRY AND MANUFACTURING SERVICES - TASK C10 CHEMICAL SYNTHESIS AND PROCESS OPTIMIZATION OF STF-1759	ALBANY MOLECULAR RESEARCH, INC.	National Institutes of Health	July 31, 2020	August 02, 2021	$0
BATTELLE ANIMAL MODELS	BATTELLE MEMORIAL INSTITUTE	Office of Assistant Secretary for Preparedness and Response - HHS	January 29, 2021	January 29, 2022	$3,713,964
THE PURPOSE OF THIS MODIFICATION IS TO INCORPORATE AN EXTENSION FOR OPTION 2, OPTION 3C AND OPTION 3D PERIODS	ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE	National Institutes of Health	March 27, 2020	May 31, 2021	$0
SARS-COV-2 APPLIED RESEARCH	UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.	Centers for Disease Control and Prevention	February 01, 2021	January 31, 2023	$1,116,539
NONHUMAN PRIMATE STUDIES COORDINATION CENTER (NHP CC) TO SUPPORT COVID-RELATED RESEARCH AT THE NATIONAL PRIMATE RESEARCH CENTERS (NPRCS)	ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE	National Institutes of Health	February 01, 2021	July 31, 2024	$1,676,885
PCMID - ESTABLISHMENT OF SMALL ANIMAL MODELS FOR SCREENING MCMS FOR THE 2019 NOVEL CORONAVIRUS (SARS-COV-2)	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	National Institutes of Health	March 23, 2020	March 22, 2021	$631,415
RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM TECH	ARETE BIOSCIENCES, LLC	National Institutes of Health	January 19, 2021	January 18, 2022	$250,000
RADX-TECH- SUPPORT SERVICES NEEDED FOR WORK PACKAGE 1	NOVEL MICRODEVICES, LLC	National Institutes of Health	January 19, 2021	January 18, 2022	$250,000
PCMID - ESTABLISHMENT OF SMALL ANIMAL MODELS FOR SCREENING MCMS FOR THE 2019 NOVEL CORONAVIRUS (SARS-COV-2)	COLORADO STATE UNIVERSITY	National Institutes of Health	March 23, 2020	June 30, 2021	$164,286
RADX-TECH - SUPPORT SERVICES NEEDED FOR WORK PACKAGE 1	ASCELLA BIOSYSTEMS, INC.	National Institutes of Health	January 13, 2021	January 12, 2022	$250,000
PROSPECTIVE ASSESSMENT OF COVID-19 AND OTHER RESPIRATORY VIRUSES IN A COMMUNITY	MARSHFIELD CLINIC	Centers for Disease Control and Prevention	August 21, 2020	August 16, 2022	$0
DETERMINE THE EPIDEMIOLOGY AND OUTCOMES ASSOCIATED WITH COVID-19 INFECTION	TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE	Centers for Disease Control and Prevention	January 06, 2021	December 30, 2021	$564,294
PROSPECTIVE, NATURAL HISTORY STUDY OF SARS COV-2 INFECTION IN WAKE FOREST HEALTH CARE WORKERS USING INNOVATIVE SAMPLING KITS	VYSNOVA PARTNERS, INC.	Centers for Disease Control and Prevention	July 01, 2020	June 30, 2022	$0
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION	SOUTHERN RESEARCH INSTITUTE	National Institutes of Health	March 27, 2020	May 26, 2021	$0
COVID19 PREDICTIVE MODELING BASELINE FOR THE WALTER REED ARMY INSTITUTE OF RESEARCH IN SILVER SPRING, MARYLAND	UNIVERSITY OF NOTRE DAME DU LAC	Department of the Army	June 01, 2020	May 31, 2021	$0
THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE COMPLETION DATE OF THE CONTRACT FOR THE BASE AND OPTION 1	ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE	National Institutes of Health	March 27, 2020	May 31, 2021	$0
THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE QUANTITY OPTIONS 1A-1J FOR SCREENING OF RODENT PHARMACOKINETICS FOR LEAD OPTIMIZATION.	EUROFINS PANLABS, INC.	National Institutes of Health	July 14, 2021	July 14, 2022	$86,400
THE PURPOSE OF THIS MODIFICATION IS TO ISSUE A STOP WORK ORDER FOR QUANTITY OPTIONS 3A AND 3B	ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE	National Institutes of Health	March 27, 2020	May 31, 2021	$0
THE NIH NEUROBIOBANK BRAIN AND TISSUE REPOSITORY (NBTR) TO PROVIDE SERVICES THAT WILL ACTIVELY ACQUIRE, RECEIVE, STORE, CURATE, PRESERVE, AND DISTRIBUTE CNS AND RELATED BIOLOGICAL SPECIMENS TO QUALIFIED INVESTIGATORS.	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	National Institutes of Health	August 28, 2019	August 31, 2024	$0
CHEMISTRY AND MANUFACTURING SERVICES - TASK C10 CHEMICAL SYNTHESIS AND PROCESS OPTIMIZATION OF STF-1759	ALBANY MOLECULAR RESEARCH, INC.	National Institutes of Health	July 31, 2020	August 02, 2021	-$562,720
ASSESS CONTAMINATION AND SURVIVABILITY OF SARS-COV-2 ON	YALE UNIVERSITY	Centers for Disease Control and Prevention	September 28, 2020	September 27, 2021	$414,315
068, CREATING ANTIBODIES TO ENABLE THE STUDY OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS IN GUINEA PIGS	GLYCOSCIENTIFIC, L.L.C.	National Institutes of Health	September 06, 2019	September 29, 2021	$0
VIRUS GENOMICS AND HUMAN MOBILITY REVEAL THE PATTERNS SARS-COV-2 SPREAD	YALE UNIVERSITY	Centers for Disease Control and Prevention	September 22, 2020	September 20, 2022	$847,346
SARS COV-2 BAA	EMORY UNIVERSITY	Centers for Disease Control and Prevention	September 28, 2020	September 27, 2021	$468,435
EXERCISE OPTION 3B - COVID-19 PROJECT	BATTELLE MEMORIAL INSTITUTE	National Institutes of Health	March 27, 2020	May 27, 2021	$1,090,940
IGF MAINTENANCE OF NIAID SPECIFIC PATHOGEN-FREE MACAQUE BREEDING COLONIES	ALPHA GENESIS, INC.	National Institutes of Health	September 16, 2020	September 29, 2024	$3,407,761
DEFINING THE ROLE OF COLLEGE STUDENTS IN SARS-COV-2 SPREAD IN THE UPPER MIDWEST	UNIVERSITY OF WISCONSIN SYSTEM	Centers for Disease Control and Prevention	September 15, 2020	September 14, 2022	$1,290,867
MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS)	NOVA SOUTHEASTERN UNIVERSITY, INC.	Centers for Disease Control and Prevention	September 14, 2020	September 13, 2024	$4,410,023
THE PURPOSE OF THIS MODIFICATION IS TO REVISE THE STATEMENT OF WORK (SOW) TO REFLECT RECENT FEEDBACK FROM THE FDA AND OWS ON THE CLINICAL DEVELOPMENT PLAN, AND TO REALLOCATE THE RESULTING FUNDING TO THE ONGOING MRNA-1273-P301 CLINICAL STUDY.	MODERNATX, INC.	Office of Assistant Secretary for Preparedness and Response - HHS	April 03, 2020	April 02, 2022	$0
CHEMISTRY AND MANUFACTURING SERVICES - TASK C10 CHEMICAL SYNTHESIS AND PROCESS OPTIMIZATION OF STF-1759	ALBANY MOLECULAR RESEARCH, INC.	National Institutes of Health	July 31, 2020	August 02, 2021	$562,720
THE NIH NEUROBIOBANK BRAIN AND TISSUE REPOSITORY (NBTR) TO PROVIDE SERVICES THAT WILL ACTIVELY ACQUIRE, RECEIVE, STORE, CURATE, PRESERVE, AND DISTRIBUTE CNS AND RELATED BIOLOGICAL SPECIMENS TO QUALIFIED INVESTIGATORS.	UNIVERSITY OF MIAMI	National Institutes of Health	August 30, 2019	August 31, 2024	$7,370
IMMUNE EPITOPE AND ANALYSIS PROGRAM	LA JOLLA INSTITUTE FOR IMMUNOLOGY	National Institutes of Health	December 15, 2018	December 14, 2025	$163,763
GENOMIC SEQUENCING OF SARS-COV-2 TO INVESTIGATE LOCAL AND CROSS-BORDER EMERGENCE AND SPREAD	SCRIPPS RESEARCH INSTITUTE, THE	Centers for Disease Control and Prevention	September 10, 2020	September 06, 2022	$2,477,409
NIH TCF TASK AREA B-1 COVID-19; SPLIT CANS; $733,849.00 POP 09/01/2020-03/20/2022	EMORY UNIVERSITY	National Institutes of Health	August 21, 2020	March 20, 2022	$0
DETERMINE THE EPIDEMIOLOGY AND RISK FACTORS FOR SECONDARY COINFECTIONS	WASHINGTON UNIVERSITY, THE	Centers for Disease Control and Prevention	September 07, 2020	September 06, 2021	$256,309
TOPIC 1.1: OUTCOMES OF SARS COV-2 INFECTIONS AMONG DIFFERENT AGE GROUPS IN THE US POPULATION	RUSH UNIVERSITY MEDICAL CENTER	Centers for Disease Control and Prevention	September 01, 2020	August 31, 2022	$13,669,039
VACCINE ADJ DISCOVERY PROGRAM (VADP)	UNIVERSITY OF MONTANA	National Institutes of Health	September 06, 2019	September 29, 2024	$0
SUPPORT NATIONWIDE ACCESS TO ANTI-MALARIAL DRUGS BY EMERGENCY USE AUTHORIZATION (EUA) FOR HOSPITALIZED, SYMPTOMATIC ADULT AND ADOLESCENT PATIENTS CONFIRMED WITH SARS-COV-2 INFECTION, THE VIRUS WHICH CAUSES COVID-19	PPD DEVELOPMENT, L.P.	Office of Assistant Secretary for Preparedness and Response - HHS	March 24, 2020	March 23, 2021	$0
NONCLINICAL SERVICES FOR THE DEVELOPMENT OF INTERVENTIONAL AGENTS FOR INFECTIOUS DISEASES	SRI INTERNATIONAL	National Institutes of Health	April 01, 2020	March 31, 2021	$107,641
NIH TCF TASK B-1	EMORY UNIVERSITY	National Institutes of Health	August 21, 2020	March 20, 2022	$733,849
MODIFICATION IS TO EXERCISE QUANTITY OPTION 2 IN THE AMOUNT OF $1,746,570 AND CHANGE THE TASK ORDER COMPLETION PERIOD FROM JANUARY 26, 2021 TO MARCH 20, 2021.	BATTELLE MEMORIAL INSTITUTE	National Institutes of Health	March 27, 2020	May 27, 2021	$1,746,570
CHARACTERIZE SEROPREVALENCE OF SARS COV-2 ANTIBODIES IN THE US POPULATION	VITALANT	Centers for Disease Control and Prevention	May 12, 2020	May 11, 2022	$16,921,661
ADJUVANT DEVELOPMENT PROGRAM	VIROVAX LLC	National Institutes of Health	September 30, 2018	September 29, 2023	$0
SUPPLEMENTAL WORK - SARS-COV-2 PRECLINICAL WORK	CHRYSALIS BIOTHERAPEUTICS, INC.	National Institutes of Health	January 30, 2017	August 31, 2021	$0
EXPANDS THE ACTIVITIES WITH RESEARCH AREA 4	UNIVERSITY OF MONTANA	National Institutes of Health	September 06, 2019	September 29, 2024	$1,199,832
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION	BATTELLE MEMORIAL INSTITUTE	National Institutes of Health	March 27, 2020	May 27, 2021	-$1,090,940
THE CONTRACTOR SHALL DETERMINE THE ANTIVIRAL INHIBITORY ACTIVITY AND CYTOTOXICITY OF TEST MOLECULES AGAINST RESPIRATORY VIRUSES USING THE SPECIFIED TEST METHOD TO IDENTIFY ACTIVE TEST MOLECULES FOR FURTHER INVESTIGATION.	UTAH STATE UNIVERSITY	National Institutes of Health	June 26, 2020	June 25, 2021	$0
THE PURPOSE OF THIS MODIFICATION IS TO INCORPORATE A NO ADDITIONAL COST EXTENSION FOR THE BASE AND QUANTITY OPTION 1 PERIODS. THE TOTAL ESTIMATED COST OF THIS TASK ORDER REMAINS UNCHANGED AT $6,749,208. THE TASK ORDER COMPLETION PERIOD REMAINS UNCHAN	ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE	National Institutes of Health	March 27, 2020	May 31, 2021	$0
SUPPLEMENTAL WORK-SARS-COV-2 OPTION - AIM 5	CHRYSALIS BIOTHERAPEUTICS, INC.	National Institutes of Health	January 30, 2017	August 31, 2021	$587,995
ADJUVANT DEVELOPMENT PROGRAM	VIROVAX LLC	National Institutes of Health	September 30, 2018	September 29, 2023	$3,385,434
NON-GMP SYNTHESIS OF GALIDESIVIR MONO-, DI-, AND TRIPHOSPHATE (BCX6870)	EUROFINS PANLABS, INC.	National Institutes of Health	July 14, 2021	July 14, 2022	$0
PCMID IDIQ	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	National Institutes of Health	March 23, 2020	March 22, 2021	$470,308
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION	SOUTHERN RESEARCH INSTITUTE	National Institutes of Health	March 27, 2020	May 26, 2021	$0
TO PROVIDE NON-GLP STANDARD, INITIAL PROFILING OF LEAD COMPOUNDS IN RODENT PHARMACOKINETICS (PK) SCREENING ASSAYS TO PROVIDE IMPORTANT DATA FOR SELECTION OF THE MOST PROMISING LEAD SERIES AS WELL AS PROVIDE DATA FOR IN VITRO-IN VIVO CORRELATION OF AS	EUROFINS PANLABS, INC.	National Institutes of Health	July 14, 2021	July 14, 2022	$129,600
COVID-19 -- ADVANCED INFORMATION TECHNOLOGY PROJECTS IN SUPPORT OF BIODEFENSE	ROMANYK CONSULTING CORPORATION	Department of the Army	September 01, 2018	August 31, 2023	$361,207
PROSPECTIVE, NATURAL HISTORY STUDY OF SARS COV-2 INFECTION IN WAKE FOREST HEALTH CARE WORKERS USING INNOVATIVE SAMPLING KITS	VYSNOVA PARTNERS, INC.	Centers for Disease Control and Prevention	July 01, 2020	June 30, 2022	$27,273,669
THE POPULATION ASSESSMENT OF TOBACCO AND HEALTH (PATH) STUDY. PERIOD OF PERFORMANCE: 04/01/2016-11/30/2024. N01DA-16-5582.	WESTAT, INC.	National Institutes of Health	April 01, 2016	November 30, 2024	$4,420,038
NIH NEUROBIOBANK BRAIN AND TISSUE REPOSITORY CONTRACT TYPE: COST, OPTION PERIOD OF PERFORMANCE: 09/01/2019 TO 08/31/2020	SEPULVEDA RESEARCH CORP	National Institutes of Health	September 01, 2019	August 31, 2024	$37,473
CENTRALIZED MOLECULAR ASSESSMENT OF SARS AND INFLUENZA VIRUS INFECTION FOR MULTI-SITE PROSPECTIVE COHORTS	MARSHFIELD CLINIC	Centers for Disease Control and Prevention	June 15, 2020	June 14, 2021	$20,553,604
PURPOSE: TO REVISE ARTICLE H.18. PUBLICATIONS AND PUBLICITY, AND TO INCORPORATE CHANGES TO APPENDIX 2 OF THE STATEMENT OF WORK AT NO ADDITIONAL COST TO THE GOVERNMENT. PERIOD OF PERFORMANCE: 09/01/2019 - 08/31/2020 (UNCHANGED) TOTAL CONTRACT AMOUN	MCLEAN HOSPITAL CORPORATION, THE	National Institutes of Health	September 01, 2019	August 31, 2024	$12,867
THE CONTRACTOR SHALL DETERMINE THE ANTIVIRAL INHIBITORY ACTIVITY AND CYTOTOXICITY OF TEST MOLECULES AGAINST RESPIRATORY VIRUSES USING THE SPECIFIED TEST METHOD TO IDENTIFY ACTIVE TEST MOLECULES FOR FURTHER INVESTIGATION.	UTAH STATE UNIVERSITY	National Institutes of Health	June 26, 2020	June 25, 2021	$354,750
PERINATAL COVID-19 IN THE UNITED STATES: SURVEILLANCE AND EPIDEMIOLOGY	CHILDREN'S HOSPITAL OF PHILADELPHIA, THE	Centers for Disease Control and Prevention	July 01, 2020	June 30, 2021	$229,479
PROSPECTIVE COHORT TO ASSESS NOVEL	UNIVERSITY OF ARIZONA	Centers for Disease Control and Prevention	June 15, 2020	June 14, 2021	$7,772,654
COVID-19. TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES.	UNIVERSITY OF CHICAGO, THE	National Institutes of Health	September 30, 2019	September 29, 2024	$319,510
NON-GMP SYNTHESIS OF GALIDESIVIR MONO-, DI-, AND TRIPHOSPHATE (BCX6870)	EUROFINS PANLABS, INC.	National Institutes of Health	July 14, 2021	July 14, 2022	$18,273
COVID-19:SUPPLEMENTAL WORK-SARS-COV-2 - PRECLINICAL WORK	CHRYSALIS BIOTHERAPEUTICS, INC.	National Institutes of Health	January 30, 2017	August 31, 2021	$912,157
COVID-19: TO DETERMINE THE ANTIVIRAL INHIBITORY ACTIVITY AND CYTOTOXICITY OF TEST MOLECULES AGAINST RESPIRATORY VIRUSES LISTED IN ONE OR MORE OF THE GROUPS BELOW USING THE SPECIFIED TEST METHOD TO IDENTIFY ACTIVE TEST MOLECULES FOR FURTHER INVESTIGAT	UTAH STATE UNIVERSITY	National Institutes of Health	June 26, 2020	June 25, 2021	$0
THE NIH NEUROBIOBANK BRAIN AND TISSUE REPOSITORY (NBTR) TO PROVIDE SERVICES THAT WILL ACTIVELY ACQUIRE, RECEIVE, STORE, CURATE, PRESERVE, AND DISTRIBUTE CNS AND RELATED BIOLOGICAL SPECIMENS TO QUALIFIED INVESTIGATORS.	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	National Institutes of Health	August 28, 2019	August 31, 2024	$81,110
THE PURPOSE OF THIS MODIFICATION IS TO ADD THE REVISED STATEMENT OF WORK (SOW) DATED JUNE 3, 2020 FOR OPTION CLIN 0003. THE CLIN VALUE REMAINS AT UNCHANGED AT $53,000,000. ALL OTHER CONTRACT TERMS AND CONDITIONS REMAIN UNCHANGED.	MODERNATX, INC.	Office of Assistant Secretary for Preparedness and Response - HHS	April 03, 2020	April 02, 2022	$0
COVID-19. MAINTENANCE OF NIAID SPECIFIC PATHOGEN-FREE MACAQUE BREEDING COLONIES	ALPHA GENESIS, INC.	National Institutes of Health	September 16, 2020	September 29, 2024	$4,607,948
DEVLOP OF A MULTI-LEVEL INTEGRATED STRATEGY FOR REGIONAL EVAL OF INFLUENZA VIRUSES	REGENTS OF THE UNIVERSITY OF MICHIGAN	Centers for Disease Control and Prevention	May 01, 2020	April 30, 2022	$0
PRE-CLINICAL MODELS OF INFECTIOUS DISEASES - ESTABLISHMENT OF SMALL ANIMAL MODELS FOR SCREENING MCMS FOR THE 2019 NOVEL CORONAVIRUS (SARS-COV-2)	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	National Institutes of Health	March 23, 2020	November 30, 2021	$446,406
PCMID - ESTABLISHMENT OF SMALL ANIMAL MODELS FOR SCREENING MCMS FOR THE 2019 NOVEL CORONAVIRUS (SARS-COV-2)	COLORADO STATE UNIVERSITY	National Institutes of Health	March 23, 2020	June 30, 2021	$328,572
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION	BATTELLE MEMORIAL INSTITUTE	National Institutes of Health	March 27, 2020	May 27, 2021	$1,088,087
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION	ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE	National Institutes of Health	March 27, 2020	May 31, 2021	$1,760,578
BAA 2020 BAYLOR SCOTT&WHITE	BAYLOR RESEARCH INSTITUTE	Centers for Disease Control and Prevention	May 04, 2020	May 03, 2021	$0
TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES.	CHILDREN'S HOSPITAL CORPORATION, THE	National Institutes of Health	September 30, 2019	September 29, 2024	$1,790,282
CHARACTERIZE SEROPREVALENCE OF SARS COV-2 ANTIBODIES IN THE US POPULATION	VITALANT	Centers for Disease Control and Prevention	May 12, 2020	May 11, 2022	$4,515,130
PRECLINICAL DEVELOPMENT OF SEMISYNTHETIC SAPONIN IMMUNOLOGICAL ADJUVANT TITERQUIL-1055 IN THE CONTEXT OF AN INFLUENZA VACCINE.	ADJUVANCE TECHNOLOGIES INC.	National Institutes of Health	June 16, 2019	December 15, 2020	$44,297
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION	BATTELLE MEMORIAL INSTITUTE	National Institutes of Health	March 27, 2020	May 27, 2021	$1,090,940
BAA 2020 BAYLOR SCOTT&WHITE	BAYLOR RESEARCH INSTITUTE	Centers for Disease Control and Prevention	May 04, 2020	May 03, 2021	$1,500,000
TO EXERCISE OPTION 3B.	ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE	National Institutes of Health	March 27, 2020	May 31, 2021	$880,289
DEVLOP OF A MULTI-LEVEL INTEGRATED STRATEGY FOR REGIONAL EVAL OF INFLUENZA VIRUSES	REGENTS OF THE UNIVERSITY OF MICHIGAN	Centers for Disease Control and Prevention	May 01, 2020	April 30, 2022	$893,518
COVID-19: TO DETERMINE THE ANTIVIRAL INHIBITORY ACTIVITY AND CYTOTOXICITY OF TEST MOLECULES AGAINST RESPIRATORY VIRUSES LISTED IN ONE OR MORE OF THE GROUPS BELOW USING THE SPECIFIED TEST METHOD TO IDENTIFY ACTIVE TEST MOLECULES FOR FURTHER INVESTIGAT	UTAH STATE UNIVERSITY	National Institutes of Health	June 26, 2020	June 25, 2021	$9,072

‹ Previous 1 2 Next ›

About this data

This data comes from the Federal Procurement Data System, which includes all contracts worth $10,000 or more. We look at all contracts that are tagged with the procurement code for COVID-19 or otherwise started in 2020 and contain “COVID-19” in the description. Department of Defense contracting data is subject to a 90-day delay before it appears in the data.